Introduction {#s1}
============

A fundamental question in biology is how cells coordinately shape functional organs with complex architecture during embryogenesis. Extensive studies have uncovered how inductive signals, such as morphogens, prime cell differentiation and morphogenesis ([@bib18]; [@bib38]), leading to segregated organs with uniquely specified cells. Due to the graded nature of the inductive signals, the initial territories of an organ primordial placode are occupied by cells with various degrees of commitment. Furthermore, cells modulate their own physical properties by changing gene expression to drive morphogenesis, but each cell behavior is dynamic and fluctuating. Therefore, mechanisms to coordinate these phenomena are of critical importance. Without a coordination mechanism, tissues would be mixed with improperly specified cells that would interfere with organ functions. The sequence of signaling, gene expression and morphogenesis is not unidirectional, and the feedback input from morphogenesis to gene expression is proposed to be crucial ([@bib7]; [@bib13]). However, the generality of the proposed feedback mechanisms from morphogenesis to gene expression and cell differentiation in a wide range of developmental systems remains to be determined.

Epithelial invagination is an important morphogenetic process in which three-dimensional tubular organs are formed from a two-dimensional flat sheet ([@bib1]; [@bib26]; [@bib43]), and the *Drosophila* trachea is a useful model system for analyzing three-dimensional epithelial morphogenesis ([@bib17]; [@bib29]). Tracheal morphogenesis is initiated by placode specification; ten pairs of tracheal placodes form in the dorsal anterior part of the epidermis in each segment by stage 10, followed by invagination, branching and fusion ([Figure 1A](#fig1){ref-type="fig"}). In this process, the tracheal placodes first appear as a group of cells expressing *trachealess* (*trh*), which is considered to be a master regulator of tracheal morphogenesis ([@bib8]; [@bib20]; [@bib50]), and then EGF signaling and mitosis synergistically drive invagination by generating centripetal pressure and inducing epithelial sheet buckling, respectively ([@bib25]; [@bib32]; [@bib34]). Finally, FGF signaling triggers tracheal branching ([Figure 1A](#fig1){ref-type="fig"}) ([@bib14]; [@bib47]).

![*trh* is essential for maintaining the invaginated tracheal structures.\
(**A**) Schematic of the tracheal morphogenesis process. For clarity, only apical surfaces are shown. (**B, C**) Live imaging of tracheal invagination in a control embryo (**B**) and a *trh* mutant (**C**). Red arrowheads: apical constriction forming a tracheal pit. Yellow circle: a mitotic cell associated with accelerated invagination, distinguished by condensed histone. Red arrows: transient invagination and return to epidermis in a *trh^1^* mutant. Gray arrows: segmental groove, which is not a tracheal structure. Par-6::GFP indicates the apical cell side, and His2Av::mRFP indicates chromosomes. Time point zero is set to the onset of germband retraction. (**D**) Activity of *R14E10-GAL4* in a control embryo monitored using *UAS-mCD8RFP*. (**E--G**) Activity of *R14E10-GAL4* in *trh^A14-3/B16-11^* mutant embryos monitored using *UAS-mCD8RFP*. Green: *D*E-cad, Magenta: mCD8RFP driven by *R14E10-GAL4*. Cells expressing RFP initiated invagination at stage 10 (**E**), and invaginated structures formed within the RFP-positive cell cluster at stage 12 (**F**). However, these invaginated structures were not observed at stage 16, and RFP-positive cells were observed in the surface epidermis (**G**). Scale bars, 10 μm.](elife-45145-fig1){#fig1}

*trh* encodes a bHLH-PAS transcription factor that is critical for tracheal morphogenesis. Its expression is primarily induced under the combinatorial control of activation through JAK-STAT signaling and inhibition through Wg and Dpp signaling before invagination ([@bib5]; [@bib50]), and STAT-responsive enhancers for *trh* have been identified ([@bib46]). After invagination, all of the tracheal cells continue expressing *trh,* while no other surrounding epithelial cells, such as epidermal cells, express this factor. However, it is not well understood how *trh* expression is strictly restricted only to invaginated tracheal cells. Although *trh* is proposed to maintain its own expression through an auto-regulatory mechanism ([@bib50]; [@bib52]), it is still unclear whether all the cells that start expressing Trh expression take part in the invagination and generation of trachea, or if some of these cells fail to invaginate, and if so, how they shut off the auto-regulatory control of *trh*.

In this article, we first show that *trh* plays a critical role in maintaining the invaginated structure but not in initiating invagination. Second, we reveal that the tracheal placode cells initiating *trh* expression later become either tracheal or epidermal cells, and the maintenance of *trh* expression is tightly associated with the change from the epithelial sheet to the invaginated structure. On the basis of our findings, we propose that the transcriptional coordination of *trh* expression, tracheal cell fate specification and invaginated structures during epithelial invagination ensures that only the invaginated cells are canalized robustly into the tracheal fate.

Results {#s2}
=======

*trh* is required to maintain invaginated structures {#s2-1}
----------------------------------------------------

We previously reported that mitosis can drive tracheal invagination, alone or in combination with EGFR signaling ([@bib25]). Although all embryonic cells undergo multiple cell divisions, mitosis-induced invagination occurs only in the tracheal placode. Non-tracheal epidermal cells quickly recover their flat epithelial architecture after mitosis, suggesting that the tracheal placode cells possess a special ability to couple mitosis with invagination and tubule formation ([@bib25]). Since *trh* is considered a master regulator of tracheal morphogenesis ([@bib20]; [@bib50]), we reasoned that *trh* is involved in this mitosis-induced invagination.

Previous studies showed that in *trh* mutants, the tracheal tissue is completely missing in late-stage embryos, and no invagination occurs ([@bib20]; [@bib50]; [@bib51]). However, in the stage-10 tracheal placode, di-phosphorylated ERK, a hallmark of EGFR activation, was detected even in *trh* mutants ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) ([@bib34]), suggesting that some early tracheal development processes were taking place. Live imaging of *trh^1^* (an EMS-induced missense allele) mutants at single-cell resolution revealed an unexpected finding: apical constriction forming a tracheal pit appeared in the center of the placode region, followed by mitosis in the pit cells and rapid, deep invagination as seen in the control, although the onset of invagination was delayed ([Figure 1B,C](#fig1){ref-type="fig"}). Over the next 90 min, the invaginated structure gradually returned to the surface epidermal layer and merged with these cells to form a segmental furrow, leaving no trace of the tracheal structure ([Figure 1C](#fig1){ref-type="fig"}). Consistent with this live imaging analysis of *trh^1^*, in fixed samples with a heteroallelic combination of TALEN-induced *trh* null alleles (*trh^A14-3^*/*trh^B16-11^*, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) ([@bib24]), would-be tracheal placode cells labeled with the *R14E10 trh* primary enhancer (containing the *trh66* STAT-responsive element that mediates stage-10 *trh* expression in the placode ([@bib46]), [Figure 1D](#fig1){ref-type="fig"}) also formed a tracheal pit ([Figure 1E](#fig1){ref-type="fig"}) and formed invaginated structures during stages 11--13 ([Figure 1F](#fig1){ref-type="fig"}). These *R14E10-*positive cells returned to the surface epidermal layer at stage 15 ([Figure 1G](#fig1){ref-type="fig"}). The appearance of invaginated structures at stage 12 and the disappearance of these structures at stages 15--16 were observed, as shown in [Figure 1F and G](#fig1){ref-type="fig"}, respectively, with 100% penetrance (stage 12: eight embryos, stage 15--16: ten embryos). In addition, the overexpression of *trh* (*trh*-OE) by *R14E10-GAL4* in the *trh* mutants rescued the phenotype ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). One of the Trh target genes is *breathless* (*btl*), which encodes an FGF receptor ([@bib35]), and we reported that FGF signaling through Btl is able to trigger invagination independent of EGF signaling and mitotic rounding ([@bib25]). However, the *btl*-OE in the *trh* mutants using *R14E10-GAL4* did not rescue tracheal formation from the transiently invaginated tracheal placodes ([Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}), indicating that other *trh* target genes are required to support FGF signaling-triggered tracheal morphogenesis. In addition, inhibiting apoptosis by *p35* did not prevent the transiently invaginated cells from returning to the epidermis, indicating that apoptotic cell removal is not the major cause of this anomaly ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). These results demonstrated that *trh* is essential for maintaining the invaginated structure, whereas it is dispensable for initiating invagination. Thus, tracheal formation proceeds by two successive and genetically separable steps: (1) invagination triggered by the mechanical forces generated through the combined activities of mitosis, EGFR, and FGFR signaling; and (2) maintenance of the invaginated structure controlled by *trh*. Since mitosis-triggered invagination was maintained in *rho bnl* mutants ([@bib25]), EGFR and FGFR signaling are dispensable for the maintenance of the invaginated structure.

Only invaginated tubule cells maintained Trh expression {#s2-2}
-------------------------------------------------------

For Trh to function as a determinant of the invaginated structures, its expression must be tightly sustained only in the invaginated cells but not in the surface epidermal cells. To reveal the relationship between *trh* expression and epithelial geometry, we attempted to analyze the impact of reducing the number of invaginated tracheal cells on Trh expression. In *rho bnl* double mutants that lose both EGF and FGF signaling in tracheal cells, tracheal invagination is impaired, and the trachea is composed of a smaller number of cells than that of the control. If a similar number of cells initiates *trh* expression in control and *rho bnl* mutants, some *trh*-positive placode cells are expected to remain in the surface epidermis, and these cells may face a conflict between their fate and tissue geometry.

JAK-STAT signaling induces *trh* expression through a STAT-responsive *trh* enhancer in the tracheal placodes at stage 10 of embryogenesis before invagination ([Figure 2A](#fig2){ref-type="fig"}) ([@bib5]; [@bib46]). After invagination, Trh is detected only in all invaginated cells, including the most proximal spiracular branch ([Figure 2C,F](#fig2){ref-type="fig"}). The number of initial Trh+ cells in the tracheal placode before invagination (stage 10) was 58.2 ± 5.1 (mean ±S.D.) in controls and 67.2 ± 8.5 in the *rho bnl* mutants, respectively, indicating that tracheal fate specification was not compromised in the *rho bnl* mutants ([Figure 2A,B,G](#fig2){ref-type="fig"}). The increase in the number of initial Trh+ cells in the *rho bnl* placodes reflects the expansion of the tracheal placode due to the earlier role of *rho* in restricting the size of tracheal placode ([@bib40]). The *R14E10* fragment contains the *trh66* STAT-responsive element that mediates stage9-10 *trh* expression ([@bib46]), and the number of initial *R14E10* + cells (57.9 ± 2.7 cells, monitored by using the *R14E10-lacZ* transgene at stage 10) is almost the same as the number of initial Trh+ cells. In contrast, after cycle-16 mitosis and invagination, the resultant tracheae of the *rho bnl* mutants were composed of a smaller number of Trh+ cells (*trh*-on cells, 31.2 ± 6.2 cells) than those of the controls (87.6 ± 6.3 cells) ([Figure 2C,D,G](#fig2){ref-type="fig"}). These findings demonstrate that in the *rho bnl* mutants, the number of initial Trh+ cells at stage 10 was reduced at stages 13--14. This reduction is due to either the disappearance of Trh+ cells from the epithelium or the loss of Trh expression in cells that failed to invaginate.

![Trh expression is maintained only in invaginated tracheal cells.\
(**A, B**) Trh expression in a tracheal placode of a control (*rho^del1^ bnl^P1^* /+) (**a**) and a *rho^del1^ bnl^P1^* mutant (**B**) embryo at stage 10 before invagination. (**C--E**) Trh and β-gal expression in a control embryo (**C**), a *rho^del1^ bnl^P1^* mutant (**D**), and a *rho^del1^ bnl^P1^* mutant with p35 overexpression (**E**) at stage 14 after invagination. β-gal and p35 expression were driven by *R14E10-GAL4*. (**F**) Schematic of the tracheal branching pattern after invagination. (**G**) Upper: Boxplot of cell numbers. Initial Trh+: the number of Trh-expressing cells before invagination, *trh*-Off: the number of cells expressing β-gal driven by *R14E10-GAL4* in the epidermis (Trh-negative) after invagination (stage 13--14), *trh*-On: the number of invaginated tracheal cells expressing Trh after invagination (stage 13--14), sum: the sum of *trh*-Off and *trh*-On. \*\*: Exact Wilcoxon-Mann-Whitney Test, p=0.001331, \*: Steel-Dwass test, p\<0.001 (for *trh*-Off, control vs *rho bnl: p*=5.3 × 10^−9^, control vs *rho bnl +p35: p*=8.3 × 10^−10^, *rho bnl* vs *rho bnl +p35: p*=3.9 × 10^−8^; for *trh*-On, control vs *rho bnl: p*=5.28 × 10^−10^, control vs *rho bnl +p35: p*=8.4 × 10^−10^, *rho bnl* vs *rho bnl +p35: p*=2.8 × 10^−10^; for sum, control vs *rho bnl: p*=3.1 × 10^−10^, control vs *rho bnl +p35: p*=2.0 × 10^−4^, *rho bnl* vs *rho bnl +p35: p*=3.2 × 10^−9^). Lower: mean numbers of *trh*-On cells and *trh*-Off cells at stages 13--14 after invagination. (**H**) Schematic of the dynamics of Trh expression during invagination. Scale bars, 10 μm.\
10.7554/eLife.45145.009Figure 2---source data 1.Source data for [Figure 2G](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}.](elife-45145-fig2){#fig2}

To discriminate these possibilities, we traced the fate of cells initiating *trh* expression by labeling them with *nls-lacZ* driven by *R14E10*. The *R14E10*-GAL4-induced *nls-lacZ* product (β-galactosidase, β-gal) persisted in the initial *trh+* cells after termination of *R14E10-GAL4* transcription, allowing us to distinguish *trh*-off (Trh^--^, LacZ^+^) and *trh*-on (Trh^+^) cells derived from the initial *trh*-on cell population after invagination (from stage 13 onward). Even in control embryos, there were *trh*-off cells (31.9 ± 6.7 cells) in the epidermis ([Figure 2C,G](#fig2){ref-type="fig"}), while all of the *trh*-on cells were found in the invaginated tubule region (87.6 ± 6.3 cells). The sum of the *trh*-on and *trh*-off cells (119.5 ± 10.5 cells) agreed well with the prediction from the number of initial Trh+ cells (58.2 ± 5.1 cells) and the number of initial R14E10 + cells (57.9 ± 2.7 cells, [Figure 3---figure supplement 2B,C](#fig3s2){ref-type="fig"}) after one round of cycle-16 mitosis during invagination. The results showed that 27% of the initial *trh+* cells lost their Trh expression, all of which remained in the epidermis. Many of the *trh*-off cells remained during the rest of embryogenesis and formed trichomes on their apical surface (data not shown), suggesting that they adopted the epidermal fate.

We next asked if the loss of *trh* expression in *trh*-off cells was due to their failure to become part of the tube by tracing the fate of *trh*-expressing cells in the *rho bnl* mutants. After invagination, the resultant tracheae were composed of a smaller number of *trh*-on cells (31.2 ± 6.2 cells), as mentioned above, and surrounded by an increased number of epidermal *trh*-off cells (50.4 ± 7.2 cells) than those of the controls, with a total of 81.6 ± 9.8 cells ([Figure 2D,G](#fig2){ref-type="fig"}). Blocking apoptosis by *p35* in the *rho bnl* mutants increased the number of both *trh*-on and *trh*-off cells ([Figure 2E,G](#fig2){ref-type="fig"}). In the *rho bnl* mutants with or without p35, 62% of the surviving initial *trh+* cells remained in the epidermis and lost their *trh* expression. These findings indicated that the reduction in *trh*-on cells in the *rho bnl* mutants was not simply due to their disappearance from the epithelium. Losses of EGF, FGF, and mitosis in the *rho CyclinA (CycA) bnl* triple mutant caused a more severe invagination defect ([@bib25]). The initial *trh* expression at stage 10 was nearly normal even in the triple mutant (53.9 ± 7.1 cells ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). If the cells maintaining Trh expression and forming tubes are predetermined before invagination, the triple mutants are supposed to possess half the number of *trh*-on cells observed in the *rho bnl* double mutants because the *CycA* mutation eliminates cycle-16 mitosis. However, although all the invaginated cells were Trh-positive, the number of Trh-on tracheal cells in these triple mutants was much smaller than expected (6.0 ± 2.5 cells, [Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}), which strongly argues against the model in which the tube-forming *trh*-on cells are predetermined before invagination. These observations support the possibility that the *trh* expression in the stage 10 tracheal placodes is maintained only in the successfully invaginated tubule cells, independent of the depth of invagination. The placode cells that failed to invaginate and remained in the epidermis lost their *trh* expression. These results imply that a mechanism exists to maintain *trh* expression only in the invaginated tubule cells and extinguish it in the superficial epidermal cells ([Figure 2H](#fig2){ref-type="fig"}).

*R15F01* is the *trh* enhancer that is sensitive to changes in tissue geometry {#s2-3}
------------------------------------------------------------------------------

A transcriptional reporter of *trh* \[*1-eve-1*, a *lacZ* enhancer trap of *trh *([@bib37]; [@bib50]) elicited reporter β-gal expression that was limited to the invaginated tracheal cells ([Figure 3B](#fig3){ref-type="fig"}), suggesting that the epidermal expression of *trh* is repressed at the level of transcription. We then tested the properties of several previously identified *trh* enhancers ([@bib46]). Among the eight *trh* upstream regions with phylogenetically conserved STAT-binding sites, *trh47* and *trh66* drive reporter expression from the early stage of tracheal development, and *trh67* is proposed to be a *trh*-dependent auto-regulatory element ([@bib46]). We found that the two primary enhancers, *trh47* ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}) and *trh66* (covered by *R14E10,* [Figure 3A](#fig3){ref-type="fig"}, [Figures 1D](#fig1){ref-type="fig"} and [2C](#fig2){ref-type="fig"}), were active in both tubule cells and the surrounding epidermal cells, suggesting that they did not reproduce the epidermal extinction of *trh*. In contrast, *trh67* did not drive reporter expression in all of the Trh-positive invaginated cells, suggesting that additional *cis*-elements control the tube-specific maintenance of *trh* expression ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}).

![*R15F10* reproduces the tubule-restricted Trh pattern.\
(**A**) Genomic positions of *R15F01*, other enhancers, and the insertion site of *1-eve-1* at the *trh* locus (**B--D**) Enhancer activity of *R15F01* monitored using *R15F01-GAL4* with *UAS-mCD8RFP* in a control (**B'**), *rho^del1^ bnl^P1^* mutant (**C**), and *rho^del1^ CycA^C8LR1^ btl^deltaOh10^* mutant (**D**) embryo. β-gal indicates the expression from a lacZ enhancer trap line for *trh*, *1-eve-1* (**B**). (**E**) Phenotype in adult cuticle pigmentation. The *R15F01-GAL4* fly had a lighter body color than the *R14E10-GAL4* fly, indicating that *R15F01* represses an adjacent *mini-yellow* gene. (**F--M**) Enhancer activity of *R15F01* monitored using the direct *lacZ* reporter in control embryos and in several invagination mutants: *rho^del1^ CycA^C8LR1^* (**H**), *rho^del1^ bnl^P1^* (**I**), *CycA^C8LR1^ bnl^P1^* (**J**), *rho^del1^ CycA^C8LR1^ bnl^P1^* (**K**), *Df(1)BSC352* (deficient in all *upd1, 2* and *3*), arrowhead: a segment with invaginated trachea, arrow: a segment without trachea (**L**), and *trh^A14-3/B16-11^ R14E10-GAL4* \> *UAS-flag::trh\[S665D\]* (**M**). Scale bars, 10 μm.](elife-45145-fig3){#fig3}

We then searched for additional *trh* enhancers from a systematic enhancer mapping resource (the FlyLight project: <https://www.janelia.org/project-team/flylight>) ([@bib21]; [@bib22]; [@bib30]) and identified another enhancer immediately upstream of the proximal *trh* promoter (*R15F01,* [Figure 3A](#fig3){ref-type="fig"}). *R15F01* showed strict tube-specific activity after invagination, and its activity was maintained in the invaginated tubule cells throughout embryogenesis ([Figure 3B', G](#fig3){ref-type="fig"}) and in postembryonic stages (not shown), in contrast to *trh47* and *trh66* (*R14E10*), which show transient activity only from embryonic stage 10 to 11 ([@bib46]). We note that a few epidermal cells sporadically showed leaked *R15F01* activity, especially when we monitored the activity using *R15F01-GAL4* reporter transgenes ([Figure 3B'](#fig3){ref-type="fig"}). In addition, when we used a direct lacZ reporter (*R15F01-lacZ*), *R15F01*'s activity became detectable in part of the tracheal placode before invagination ([Figure 3F](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2G](#fig3s2){ref-type="fig"}), slightly later than that of the other early enhancers (*trh47* or *R14E10*). In addition, we noticed that *R15F01* repressed the function of an adjacent *mini-yellow* gene (*mini-y* included in *attP40 or attP2*, a transgene landing site on chromosome 2L or chromosome 3L, respectively \[[@bib15]\]) in the adult epidermis ([Figure 3E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). The function of the endogenous *yellow* gene on chromosome X was not affected (data not shown), suggesting that *R15F01* represses *mini-y* expression in cis. These results suggested that *R15F01* is a cis-regulatory module (CRM) that simultaneously functions as an enhancer in tracheal tube cells and a silencer in epidermal sheet cells.

Using the mutant combinations that prevented invagination to various degrees (combinations of *rho, bnl* and *CycA*), no or only a few epidermal cells showed *R15F01* activity, while the small tracheal tubes were *R15F01-*positive irrespective of the depth of invagination ([Figure 3C,D,H--K](#fig3){ref-type="fig"}). In the *rho bnl* mutants, *R15F01* activation was detected at stage 10 before invagination. The number of initial *R15F01* + cells in the *rho bnl* mutants before cycle-16 mitosis and invagination (39.5 ± 4.7 cells, [Figure 3---figure supplement 2D,G](#fig3s2){ref-type="fig"}) is smaller than that of control embryos (47.3 ± 6.1, [Figure 3---figure supplement 2G](#fig3s2){ref-type="fig"}), indicating that EGF signaling is involved in the initial activation but is not essential. In addition, the number is larger than the number of invaginated cells with Trh expression after cycle-16 mitosis (Trh-on cells) in the *rho bnl* mutants (two times 37.7 ± 6.3 cells VS *trh*-on cells 31.2 ± 6.2 cells ([Figure 2G](#fig2){ref-type="fig"}); note that the number of cells is doubled after cycle-16 mitosis), suggesting that *R15F01* activity is controlled by a multistep mechanism. Even in *unpaired 1* (*upd1*), *upd2,* and *upd3* triple mutants (*Df(1)BSC352*), which are deficient for all Upd cytokines and are unable to activate JAK-STAT signaling, invaginated trachea appeared in some segments, and only these invaginated cells became *R15F01-*active ([Figure 3L](#fig3){ref-type="fig"}). These results indicate that the tubule-specific maintenance of *R15F01* activity after invagination is independent of JAK-STAT, EGFR, and FGFR signaling. These results also support the idea that the tube-forming *trh*-on cells are not predetermined before invagination and that only the successfully invaginated cells secondarily sustain the *R15F01* activity for Trh expression independent of the initial induction of its activation.

To analyze the contribution of *trh* to tube-specific *R15F01* maintenance, we monitored *R15F01* activity in *trh* mutants. *R15F01* activation was detected in the *trh* mutants before invagination, but the number of β-gal-positive cells (29.4 ± 6.7) was smaller than that of the control (47.3 ± 6.1) ([Figure 3---figure supplement 2E,G](#fig3s2){ref-type="fig"}), indicating that *trh* is involved in the initial activation of *R15F01* but is not essential. After mitosis cycle 16, transient invagination and disappearance of invaginated architecture in the *trh* mutants, 19.1 ± 6.8 cells still maintained *R15F01* reporter expression at stage 15 ([Figure 3---figure supplement 2F,H](#fig3s2){ref-type="fig"}). Because this number is smaller than the number of initially activated cells, *R15F01* activity could be maintained in a *trh*-independent manner. As mentioned above, in addition, *trh*-OE in the *trh* mutants by *R14E10-GAL4* (early transient activation of *trh* in placodes, and no secondary regulation of *trh* expression) could rescue tracheal morphogenesis, and more cells took on a tubular architecture than in the *trh* mutants ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). We found that all these invaginated cells showed *R15F01* activity ([Figure 3M](#fig3){ref-type="fig"}, β-gal), while some *trh*-OE cells did not take part in invagination, and these surface-remaining cells did not show *R15F01* reporter expression even when we overexpressed a phosphomimetic active form of Trh ([Figure 3M](#fig3){ref-type="fig"}, RFP + epidermal cells). These results strongly suggest that Trh is not sufficient to maintain longer *R15F01* activity and that secondary regulatory mechanisms that are potentially associated with invagination are required. *trh*-OE by *R15F01-GAL4* in the *trh* mutants could also partially rescue tracheal morphogenesis ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). Because of the later onset of *R15F01* and/or the smaller number of *R15F01*-active cells than in *R14E10* ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), the invagination defect of the *trh* mutants was not rescued at stage 12. On the other hand, in later stage 15, *R15F01*-positive cells were able to maintain invaginated structures, although they showed an incomplete branching pattern, possibly due to a limited number of *R15F01-*positive cells.

The *R15F01* CRM possesses both tracheal enhancers and epidermal silencers {#s2-4}
--------------------------------------------------------------------------

To identify functional elements within the 3963 bp fragment of *R15F01*, we divided *R15F01* into eight fragments (D1-D8), constructed four deletions (del1-del4) and assayed their regulatory activity before invagination (stage-10 tracheal placode), their activity in the trachea and epidermis after invagination (from stage 13 onward), and their *cis*-inhibition effect on *mini-yellow* in adult flies ([Figure 4A](#fig4){ref-type="fig"}). The results showed that the enhancer activity for tracheal expression was mapped to two sub-fragments: D7, which was sufficient to drive expression in the tracheal placode and invaginated tracheal tubules ([Figure 4A,D,H,I](#fig4){ref-type="fig"}), and D1, which drove tracheal expression after invagination in a somewhat sporadic manner ([Figure 4A,C,F,G](#fig4){ref-type="fig"}). No other sub-fragment showed tracheal enhancer activity ([Figure 4---figure supplement 1B--G](#fig4s1){ref-type="fig"}). In addition, fragment D7 also drove expression in the epidermal region near the tracheal pit ([Figure 4D,I](#fig4){ref-type="fig"}), indicating that D7 drives both tracheal and epidermal expression and is not sufficient to reproduce the tube-restricted pattern after invagination. Second, the *mini-y* silencer activity was mapped to sub-fragment D1, and its removal from *R15F01* (i.e., the del4 construct) abrogated this *mini-yellow* silencing ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}).

![The *R15F10* CRM contains multiple tracheal enhancers and epidermal silencers.\
(**A**) Summary of the domain mapping of *R15F01*. ± indicates sporadic expression. (**B--E**) Activities of *R15F01* (full length), D1, D7, and del4 monitored using GAL4 and *UAS-mCD8RFP*. D7 activated RFP expression in both tracheal and surrounding epidermal cells (arrows in E). D1 induced RFP expression in a sporadic manner. (**F--I**) Activities of D1 and D7 monitored using the direct *lacZ* reporter at stage 10 (before invagination), stage 11 (during invagination), and stage 15 (after invagination). D7 showed enhancer activity in the tracheal placodes before invagination, but D1 activated the reporter in tracheal cells after invagination. Arrows in I indicate epidermal expression of β-gal. Scale bars, 10 μm.](elife-45145-fig4){#fig4}

The epidermal enhancer activity of D7 in embryos was not detected in full-length *R15F01,* suggesting that an epidermal silencer that represses D7's epidermal activity must reside in another part of *R15F01*. D1 is likely to contain this activity, since it possesses the silencer activity for *mini-yellow*, and the combination of D1 with D7 in constructs del2 and del3 reproduced the expression pattern of *R15F01* ([Figure 4A](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1I,J](#fig4s1){ref-type="fig"}). In addition, the del4 construct, which did not contain the D1 or D2 fragment, also showed epidermal suppression of D7 activity ([Figure 4A,E](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1K](#fig4s1){ref-type="fig"}). These data indicated that silencer elements reside in at least two regions, one in the D1-D2 fragment with *mini-y* silencer activity and the other in the region included in del4 (in the D3 to D6 and/or D8 fragment).

To examine whether these silencers could act on a heterologous epidermal enhancer, we constructed chimeric reporters consisting of the *shavenbaby* (*svb*) epidermal enhancer and sub-fragments of *R15F01* ([Figure 5A](#fig5){ref-type="fig"}). The *svb* E6B element enhances reporter gene expression in the dorsal epidermal cells that form trichomes ([Figure 5B,D](#fig5){ref-type="fig"}) ([@bib12]). We found that the fragments containing D1 and D2 (D1-D2), from D3 to D6 (D3-D6), and from D1 to D6 (in the del1 construct) were able to silence the *svb* E6B activity ([Figure 5C,E,F](#fig5){ref-type="fig"}). Since the D1-D2 and D3-D6 inserts have no overlap, these data confirmed that *R15F01* contains multiple and redundant silencer elements that act dominantly over the *svb* E6B epidermal enhancers.

![The *R15F01* epidermal silencers counteract a heterologous epidermal enhancer.\
(**A**) Schematic of chimeric reporters with *svb-E6B* and *R15F01* fragments (**B, C**) Reporter β-gal expression (magenta or fire) from *E6B-lacZ* and *E6B-\[D3-6\]-lacZ* integrated at the *attP40* site. The epidermal β-gal expression in *E6B-\[D3-6\]-lacZ* was significantly weaker than that in *E6B-lacZ*. (**D--F**) Reporter β-gal expression (magenta or fire) from *E6B-lacZ*, *E6B-\[D1-2\]-lacZ*, and *E6B-\[del1\]-lacZ* integrated at the *ZH-51c* site. The epidermal β-gal expression in *E6B-\[D1-2\]-lacZ* and *E6B-\[del1\]-lacZ* was significantly weaker than that in *E6B-lacZ*, while both showed tracheal reporter expression. (**G--I**) Reporter GFP expression (green or fire) in (**G**) *arm-GAL4* \>*3×UAS-GAP43GFP*, (**H**) *arm-GAL4* \>*3 × UAS-R15F01-GAP43GFP*, and (**I**) *3×UAS-GAP43GFP* only. Both *3×UAS-GAP43GFP* and *3×UAS-R15F01-GAP43GFP* transgenes were integrated at the *attP2* site. The epidermal GFP expression (the surface of embryos) in *arm-GAL4* \>*3×UAS-R15F01-GAP43GFP* was significantly weaker than that of *3×UAS-GAP43GFP*, while hindgut GFP expression was detectable. Embryos possessing only *3×UAS-GAP43GFP* showed tracheal GFP expression but not hindgut expression. Arrows indicate the hindgut.](elife-45145-fig5){#fig5}

To further characterize the difference in the silencing activity of *R15F01* between epidermal and internal epithelial tissues, we constructed another chimeric reporter in which the UAS element was fused to *R15F01*. When we crossed the 3×UAS-GFP reporter with arm-GAL4, which is an epithelial ubiquitous GAL4 driver ([@bib42]), GFP expression was detected ubiquitously, with an intense signal in epidermal and hindgut cells ([Figure 5G](#fig5){ref-type="fig"}). Then, we crossed the 3×UAS*-R15F01*-fused GFP reporter with arm-GAL4, and epidermal GFP expression was nearly undetectable, while hindgut GFP expression was still detectable ([Figure 5H](#fig5){ref-type="fig"}). The tracheal GFP signal was enhanced, possibly due to the tracheal enhancers in *R15F01*. Embryos harboring only the 3×UAS*-R15F01* reporter without arm-GAL4 showed the tracheal GFP signal but not hindgut GFP expression ([Figure 5I](#fig5){ref-type="fig"}), indicating that the hindgut activity was driven by arm-GAL4. These results are also consistent with the notion that *R15F01* silences enhancer activities in the surface epidermis but not in internal tubular organs.

Discussion {#s3}
==========

Here, we showed that during *Drosophila* tracheal morphogenesis, (1) the master regulator *trh* is essential for maintaining the invaginated structure of the trachea but is dispensable for driving invagination of the placode, and (2) *trh* expression is maintained in invaginated cells, while its expression in surface epidermal cells is actively repressed. We propose that under these two mechanisms, the only successfully invaginated cells establish tight coupling between different hierarchies, tracheal cell fate and tubular architecture. *trh*-positive placode cells that do not take part in tubules lose their *trh* expression and adopt the epidermal fate with a flat sheet architecture.

Driving forces of morphogenesis and the stable structures of epithelial tissue {#s3-1}
------------------------------------------------------------------------------

We found that in *trh* mutants, a subset of the would-be tracheal placode cells undergo invagination but fail to maintain the invaginated structure. This observation contradicts previous reports claiming that *trh* is required for invagination ([@bib20]; [@bib50]). We consider that our results based on live imaging of early tracheal invagination processes identified crucial tracheal cell behavior that was missed in previous works that mainly focused on late embryonic phenotypes. The phenotype of *trh* mutants indicates that the conversion of the epithelial sheet of the tracheal placode into a tube through invagination and the stabilization of the invaginated structures are genetically separable steps. In addition, inductive signals, such as JAK/STAT signaling, are considered to prime both tracheal differentiation (i.e., *trh* expression) and invagination separably. This finding is also consistent with the idea that morphogenetic movement and cell differentiation can be uncoupled ([@bib19]). We suggest that epithelial tissue can assume two alternative stable structures, sheet or tube, and according to cell fate, each epithelial tissue assumes one of these structures. In the tracheal system, invagination forces include the contraction of myosin cables regulated by EGF signaling and a cell migratory force stimulated by FGF signaling ([@bib25]; [@bib32]; [@bib34]). If both signaling pathways are absent, transient tissue instability caused by clustered mitosis allows invagination ([@bib25]). This mitotic cue is sufficient for the conversion of the Trh + placodes from the sheet state to the more stable tube state. Once invaginated by any driving forces, the tracheal cells robustly maintain the invaginated structure under the control of Trh.

In *trh* mutants, although the placode cells are able to initiate invagination, the degree of invagination is much smaller than that of the control. This is consistent with our recent report that *trh* controls the propagation of EGFR activation but not the initial activation of EGFR in the placodes ([@bib34]), indicating that *trh* contributes to tracheal invagination through EGFR signaling propagation in part. However, even when both EGFR and FGFR signaling are lost, Trh+ cells are able to maintain the invaginated structure. In addition, although *btl,* which encodes an FGFR, is one of the important downstream genes of *trh* and FGFR signaling can trigger invagination when EGFR signaling and mitosis 16 are eliminated in the placodes, the *btl*-OE in the *trh* mutants was not sufficient to rescue invagination and tubule maintenance. These results indicate that the maintenance of the invaginated structure is largely dependent on *trh* in an EGFR and FGFR signaling-independent manner.

While canonical tissue-folding processes are driven by apically concentrated myosin through active apical constriction ([@bib31]), tracheal invagination has unique properties, including passive apical constriction under centripetal pressure from neighboring cells, the acceleration of the invagination through mitotic cell rounding ([@bib25]), and a lack of apically concentrated myosin localization in the invaginating cells ([@bib25]). This is consistent with a recent report that myosin regulatory light chain depletion using the deGradFP system does not cause significant abnormalities in tracheal morphogenesis ([@bib33]). Candidates for Trh-downstream effectors that maintain invaginated structures are Crossveinless-c (cv-c), a Rho family GTPase-activating protein (RhoGAP), and Crumbs (Crb), both of which are expressed in the tracheal cells under the control of *trh* ([@bib4]; [@bib28]; [@bib41]). However, both *cv-c* mutants and *crb* mutants are able to maintain their tubular tracheal geometry ([@bib6]; [@bib28]), suggesting that *trh* controls the epithelial tissue geometry through the activation of multiple genes. It has recently been reported that in the salivary gland, the overexpression of a constitutive active form of Arp2/3 activator causes reversal of invaginated structures into epidermis ([@bib9]), suggesting that the difference in F-actin organization is also important to stabilize epithelial structure (sheet or tube). In addition, *trh* is also known to re-organize microtubule structures ([@bib3]). During dorsal fold formation in the gastrulating fly embryo, the invaginating cells do not show apical myosin enrichment, whereas the apical microtubule network plays an important role in cell shortening through a polarity-dependent basal shift of AJs ([@bib48]; [@bib49]). Therefore, re-organization of both F-actin and microtubule architectures, but not apically concentrated myosin, might synergistically support the maintenance of invaginated structures. Further investigation of the *trh*-downstream transcriptome profile and tubule stabilization mechanisms will be important for understanding the diversity of cellular mechanisms of epithelial morphogenesis.

Induction, priming, and completion of tracheal cell differentiation coupled with epithelial morphogenesis {#s3-2}
---------------------------------------------------------------------------------------------------------

We found that *trh* expression is strictly maintained only in invaginated cells, whereas it is extinguished in cells remaining in the adjacent surface epidermis, irrespective of the depth of invagination. Because some of the initial Trh-expressing cells do not invaginate and lose their Trh expression, the initial priming of Trh expression is not sufficient for cells to take part in invagination and does not result in autocatalytic maintenance of its expression. Therefore, there should be a mechanism that determines cells that maintain Trh expression after the initial primed state. One possibility is that these cells are predetermined independent of initial priming of *trh* expression before invagination and then form the tubular architecture precisely. The other possibility is that maintenance of Trh expression is tightly associated with invagination. Our data using various invagination mutants (especially the comparison between *rho bnl* mutants and *rho CycA bnl* mutants, [Figure 2](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, as mentioned in the results section above) strongly suggest that the cells that retain *trh* expression and invaginated structures are not predetermined, and tissue-geometry-dependent mechanisms are involved in tight coupling of invaginated structures and Trh expression. Since Trh is essential for stabilizing invaginated structures, this coupling may ensure that only invaginated cells canalize robustly into the tracheal fate and further supports the formation of a tubular tracheal system after invagination.

Our findings strongly suggest that the *R15F01* CRM is crucial for invagination-restricted Trh expression and is composed of multiple enhancers and redundant epidermal silencers. We also note that because *R15F01* is activated in part of the placode cells before invagination, there should be a mechanism for this transient activation, regardless of tissue architecture. After invagination, *R15F01* activity is maintained only in invaginated cells independent of the degree of invagination, suggesting that *R15F01* senses both initial placode activation cues and morphogenetic invagination cues for *trh* expression. In addition, *R15F01* is also reported to be a conserved Polycomb response element (PRE) ([@bib16]; [@bib44]). ChIP signals for several Polycomb factors, such as Polycomb, Pleiohomeotic, Polyhomeotic distal, and Dorsal switch protein 1, are highly concentrated along the *R15F01* region, especially in the D1 region, which shows strong silencer activity for *mini-y*, and this pattern is conserved across *Drosophila* species ([@bib44]) (ChIP atlas; <http://chip-atlas.org> and GSE60428). Since these analyzes were performed using whole embryos, it is still unclear in which cells these Polycomb factors associate with the *R15F01* locus. It was also recently reported that some developmental enhancers can also function as PREs ([@bib11]). These findings suggest that *R15F01* functions as a developmental enhancer in tracheal cells, while it operates as a PRE in other cells, including epidermal cells. If so, counteracting this PRE activity at the *trh* locus only in invaginated cells may be the critical step for coupling Trh expression and tubular architecture.

Control mechanisms of *R15F01* CRM activity and Trh maintenance {#s3-3}
---------------------------------------------------------------

The terminal differentiation of tracheal cells is likely to be a consequence of the relocation of tracheal primordial cells from the surface epidermis to the inside of the trachea and the suppression of the epidermal silencer activity of *trh*. An essential remaining question is how the tracheal cells couple Trh expression with invaginated structures during morphogenesis. This study showed that known signaling pathways involved in early tracheal morphogenesis, such as JAK-STAT, EGFR and FGFR signaling, are dispensable for maintaining *R15F01* activity only in invaginated cells. One possible mechanism is sensing the change in epithelial geometry from sheet to tube through mechano-transduction pathways. Cells are known to sense rigidity in their environment, mechanical stress, and their own morphology and cytoskeletal architecture and to control gene expression and chromatin organization in response to these factors ([@bib7]; [@bib23]; [@bib27]; [@bib36]). Another possibility is that the cell can detect geometrical conversion through a change in the local concentration of secreted molecules ([@bib13]). Buckling and bending of the intestinal epithelium affect the local concentration of Sonic hedgehog (Shh) to help define the positions of stem cells in chicks ([@bib45]). In addition, lumen formation and the luminal accumulation of FGF promote differentiation at the zebrafish lateral line ([@bib10]). At present, we do not have evidence that any signaling pathways affected by secreted ligands or known mechano-transduction pathways, such as Hippo, Src-Arm, or Ca^2+^, are involved in invagination-responsive Trh expression. In addition, it is still unclear whether cells directory sense the invaginated structure to terminally differentiate into tracheal cells or whether the relocation from the surface epidermis to the inside of the embryos just allows cells to acquire a non-epidermal fate. It remains a future challenge to discriminate among these possibilities.

Because all tissues and organs must match their architecture with their cellular phenotype to function properly, similar canalization mechanisms that couple gene expression, cell fate, and tissue geometry may play fundamental roles in shaping functional organs. Although morphogenetic feedback is proposed to be important for organogenesis, the cellular mechanisms for sensing tissue geometry have only begun to be elucidated. Further study into the cellular and genetic mechanisms by which tracheal cells monitor the process of morphogenesis and adjust their cell fate would help us understand the robustness of animal morphogenesis.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                 Designation                            Source or\                                                       Identifiers                                                      Additional\
  (species) or\                                                        reference                                                                                                                         information
  resource                                                                                                                                                                                               
  ----------------------------- -------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------------------------------
  Genetic reagent\              trh\[1\]                               Kyoto stock center                                               DGRC:106845;\                                                    
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBal0017036                                                

  Genetic reagent\              trh\[A14-3\]                           [@bib24]                                                         FLYB: FBal0344676                                                
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              trh\[B16-11\]                          [@bib24]                                                         FLYB: FBal0344695                                                
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              1-eve-1                                Bloomington Drosophila Stock Center                              BDSC: 8744;\                                                     FlyBase symbol: P{ET-L}trh-1-eve-1
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBti0002897                                                

  Genetic reagent\              R14E10-GAL4(attP2)                     Bloomington Drosophila Stock Center                              BDSC: 48641                                                      
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-GAL4(attP2)                     Bloomington Drosophila Stock Center                              BDSC: 45071;\                                                    FlyBase symbol: P{GMR15F01-GAL4}attP2
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBti0133347                                                

  Genetic reagent\              UAS-mCD8.ChRFP                         Bloomington Drosophila Stock Center                              BDSC: 27392;\                                                    FlyBase symbol: P{UAS-mCD8.ChRFP}3
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBti0115769                                                

  Genetic reagent\              UAS-nls-lacZ                           Kyoto stock center                                               DGRC:108782;\                                                    FlyBase symbol: P{UAS-GFP::lacZ.nls}30.1
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBti0002781                                                

  Genetic reagent\              UAS-flag::trh                          PMID: [11740943](https://www.ncbi.nlm.nih.gov/pubmed/11740943)   FLYB: FBal0150204                                                
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              UAS-flag::trh\[S665D\]                 PMID: [11740943](https://www.ncbi.nlm.nih.gov/pubmed/11740943)   FLYB: FBal0150205                                                
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              UAS-btl::GFP                           Bloomington Drosophila Stock Center                              BDSC: 41802;\                                                    FlyBase symbol: P{UAS-btl::GFP-S65T}3
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBti0148917                                                

  Genetic reagent\              UAS-p35                                Kyoto stock center                                               DGRC: 108018;\                                                   FlyBase symbol: P{UAS-p35.H}BH1
  (*Drosophila melanogaster*)                                                                                                           FLYB:FBti0012594                                                 

  Genetic reagent\              rho\[del1\]                            PMID: [2110920](https://www.ncbi.nlm.nih.gov/pubmed/2110920)     FLYB: FBal0017860                                                
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              bnl\[P1\]                              Bloomington Drosophila Stock Center                              BDSC: 6384;\                                                     
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBal0057745                                                

  Genetic reagent\              CycA\[C8LR1\]                          Bloomington Drosophila Stock Center                              BDSC: 6627;\                                                     
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBal0065308                                                

  Genetic reagent\              btl\[deltaOh10\]                       [@bib35]                                                         FLYB: FBal0083056                                                
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              Df(1)BSC352                            Bloomington Drosophila Stock Center                              BDSC: 24376;\                                                    
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBab0045128                                                

  Genetic reagent\              Par6::GFP                              PMID: [18854163](https://www.ncbi.nlm.nih.gov/pubmed/18854163)   FLYB: FBal0243990                                                
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              His2Av::mRFP                           Bloomington Drosophila Stock Center                              BDSC: 23651;\                                                    FlyBase symbol: P{His2Av-mRFP1}II.2
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBti0077845                                                

  Genetic reagent\              His2Av::mRFP                           Bloomington Drosophila Stock Center                              BDSC: 23650;\                                                    FlyBase symbol: P{His2Av-mRFP1}III.1
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBti0077846                                                

  Genetic reagent\              arm-GAL4\[11\]                         Kyoto stock center                                               DGRC:106387;\                                                    FlyBase symbol: P{GAL4-arm.S}11
  (*Drosophila melanogaster*)                                                                                                           FLYB: FBti0002793                                                

  Genetic reagent\              trh66-lacZ                             [@bib46]                                                         FLYB: FBal0265118                                                
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-lacZ(attP40)                    this paper                                                       N/A                                                              lacZ reporter with R15F01 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R14E10-lacZ(attP40)                    this paper                                                       N/A                                                              lacZ reporter with R14E10 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D1-lacZ(attP40)                 this paper                                                       N/A                                                              lacZ reporter with R15F01-D1 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D2-lacZ(attP40)                 this paper                                                       N/A                                                              lacZ reporter with R15F01-D2 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D3-lacZ(attP40)                 this paper                                                       N/A                                                              lacZ reporter with R15F01-D3 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D4-lacZ(attP40)                 this paper                                                       N/A                                                              lacZ reporter with R15F01-D4 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D5-lacZ(attP40)                 this paper                                                       N/A                                                              lacZ reporter with R15F01-D5 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D6-lacZ(attP40)                 this paper                                                       N/A                                                              lacZ reporter with R15F01-D6 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D7-lacZ(attP40)                 this paper                                                       N/A                                                              lacZ reporter with R15F01-D7 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D8-lacZ(attP40)                 this paper                                                       N/A                                                              lacZ reporter with R15F01-D8 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-del1-lacZ(ZH-51C)               this paper                                                       N/A                                                              lacZ reporter with R15F01-del1 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-del1-lacZ\[FS\](attP40)         this paper                                                       N/A                                                              lacZ reporter with R15F01-del1 fragment, but lacZ CDS contains a frameshift mutation
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-del2-lacZ(attP40)               this paper                                                       N/A                                                              lacZ reporter with R15F01-del2 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-del3-lacZ(attP40)               this paper                                                       N/A                                                              lacZ reporter with R15F01-del3 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-del4-lacZ(attP40)               this paper                                                       N/A                                                              lacZ reporter with R15F01-del4 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              trh47-GAL4(attP2)                      this paper                                                       N/A                                                              GAL4 transgene with trh47 regulatory region
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              trh67-GAL4(attP2)                      this paper                                                       N/A                                                              GAL4 transgene with trh67 regulatory region
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-GAL4(attP40)                    this paper                                                       N/A                                                              GAL4 transgene with R15F01 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R14E10-GAL4(attP40)                    this paper                                                       N/A                                                              GAL4 transgene with R14E10 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D1-GAL4(attP2)                  this paper                                                       N/A                                                              GAL4 transgene with R15F01-D1 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-D7-GAL4 (attP2)                 this paper                                                       N/A                                                              GAL4 transgene with R15F01-D7 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              R15F01-del4-GAL4 (attP2)               this paper                                                       N/A                                                              GAL4 transgene with R15F01-del4 fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              svbE6B-lacZ(attP40)                    this paper                                                       N/A                                                              lacZ reporter with svbE6B regulatory region, integrated into attP40
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              svbE6B-D3-6-lacZ(attP40)               this paper                                                       N/A                                                              lacZ reporter with svbE6B-R15F01-D3-6 fusion fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              svbE6B-lacZ(ZH-51C)                    this paper                                                       N/A                                                              lacZ reporter with svbE6B regulatory region, integrated into ZH-51C
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              svbE6B-D1-2-lacZ(ZH-51C)               this paper                                                       N/A                                                              lacZ reporter with svbE6B-R15F01-D1-2 fusion fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              svbE6B-del1-lacZ(ZH-51C)               this paper                                                       N/A                                                              lacZ reporter with svbE6B-R15F01-del1 fusion fragment
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              3×UAS-GAP43GFP (attP2)                 this paper                                                       N/A                                                              GFP reporter with3 × UAS sequences
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Genetic reagent\              3×UAS-R15F01-GAP43GFP (attP2)          this paper                                                       N/A                                                              GFP reporter with 3 × UAS-R15F01 fusion
  (*Drosophila melanogaster*)                                                                                                                                                                            

  Antibody                      anti-β-galactosidase                   MP Biomedicals                                                   55976,\                                                          rabbit polyclonal, 1:5000 for IHC
                                                                                                                                        RRID:[AB_2334934](https://scicrunch.org/resolver/AB_2334934)     

  Antibody                      anti-β-galactosidase                   Abcam                                                            ab9361,\                                                         chick polyclonal, 1:1000 for IHC
                                                                                                                                        RRID:[AB_307210](https://scicrunch.org/resolver/AB_307210)       

  Antibody                      anti-DE-cad                            Developmental Studies Hybridoma Bank                             DSHB: DCAD2,\                                                    rat monoclonal, 1:20 for IHC
                                                                                                                                        RRID:[AB_528120](https://scicrunch.org/resolver/AB_528120)       

  Antibody                      anti-RFP                               MBL                                                              M155-3,\                                                         mouse monoclonal, 1:300 for IHC
                                                                                                                                        RRID:[AB_1278880](https://scicrunch.org/resolver/AB_1278880)     

  Antibody                      anti-DsRed                             BD Biosciences                                                   632397                                                           rabbit polyclonal, 1:5000 for IHC

  Antibody                      anti-GFP                               Molecular Probes                                                 A-11122,\                                                        rabbit polyclonal, 1:300 for IHC
                                                                                                                                        RRID:[AB_221569](https://scicrunch.org/resolver/AB_221569)       

  Antibody                      anti-Trh                               other                                                                                                                             rabbit polyclonal, 1:100 for IHC, Dr Jordi Casanova (IRB Barcelona)

  Antibody                      Anti-MAP Kinase, Activated             Signa-Aldrich                                                    M8159,\                                                          mouse monoclonal, 1:1000 for IHC
                                                                                                                                        RRID:[AB_477245](https://scicrunch.org/resolver/AB_477245)       

  Antibody                      anti-rabbit IgG Alexa Fluor Plus 488   Molecular Probes                                                 A-32731,\                                                        1:300 for IHC
                                                                                                                                        RRID:[AB_2633280](https://scicrunch.org/resolver/AB_2633280)     

  Antibody                      anti-rabbit IgG Alexa Fluor Plus 555   Molecular Probes                                                 A-32732,\                                                        1:300 for IHC
                                                                                                                                        RRID:[AB_2633281](https://scicrunch.org/resolver/AB_2633281)     

  Antibody                      anti-mouse IgG Alexa Fluor Plus 488    Molecular Probes                                                 A-32723,\                                                        1:300 for IHC
                                                                                                                                        RRID:[AB_2633275](https://scicrunch.org/resolver/AB_2633275)     

  Antibody                      anti-mouse IgG Alexa Fluor Plus 555    Molecular Probes                                                 A-32727,\                                                        1:300 for IHC
                                                                                                                                        RRID:[AB_2633276](https://scicrunch.org/resolver/AB_2633276)     

  Antibody                      anti-rabbit IgG Alexa Fluor 488        Molecular Probes                                                 A-11034,\                                                        1:300 for IHC
                                                                                                                                        RRID:[AB_2576217](https://scicrunch.org/resolver/AB_2576217)     

  Antibody                      anti-rabbit IgG Alexa Fluor 555        Molecular Probes                                                 A-21429,\                                                        1:300 for IHC
                                                                                                                                        RRID:[AB_141761](https://scicrunch.org/resolver/AB_141761)       

  Antibody                      anti-mouse IgG Alexa Fluor 488         Molecular Probes                                                 A-11029,\                                                        1:300 for IHC
                                                                                                                                        RRID:[AB_138404](https://scicrunch.org/resolver/AB_138404)       

  Antibody                      anti-mouse IgG Alexa Fluor 555         Molecular Probes                                                 A-21424,\                                                        1:300 for IHC
                                                                                                                                        RRID:[AB_141780](https://scicrunch.org/resolver/AB_141780)       

  Antibody                      anti-Rat IgG DyLignt 649               Jackson ImmunoResearch                                           112-495-167                                                      1:300 for IHC

  Antibody                      anti-Rat IgG DyLignt 650               Abcam                                                            ab102263,\                                                       1:50 for IHC
                                                                                                                                        RRID:[AB_10711247](https://scicrunch.org/resolver/AB_10711247)   

  Antibody                      anti-chick IgY Alexa Fluor 488         Abcam                                                            ab150173                                                         1:300 for IHC

  Antibody                      anti-chick IgY Alexa Fluor 555         Abcam                                                            ab150174                                                         1:300 for IHC

  Antibody                      anti-mouse IgG-biotin                  Jackson ImmunoResearch                                           715-065-151,\                                                    1:500 for TSA amplification
                                                                                                                                        RRID:[AB_2340785](https://scicrunch.org/resolver/AB_2340785)     

  Commercial assay or kit       VECTASTAIN Universal Elite ABC Kit     Vector Laboratories                                              PK-6100                                                          Use Reagent A and Reagent B for TSA amplification

  Commercial assay or kit       TSA Cyanine 3 System                   PerkinElmer                                                      NEL704A001KT                                                     1:50 for TSA amplification
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fly strains {#s4-1}
-----------

The fly strains used in this study are listed in the Key Resources Table.

Plasmid construction and transgenesis {#s4-2}
-------------------------------------

Plasmids were constructed using PrimeSTAR max or PrimeSTAR HS (Takara Bio) and an in-fusion PCR cloning kit (Clontech) unless otherwise noted. For pBPGUw-R15F01 and pBPGUw-R14E10, each corresponding region was amplified from genomic DNA, subcloned into pENTR-TOPO, and recombined into pBPGUw \[pBPGUw was a gift from Gerald Rubin (Addgene plasmid \#17575) ([@bib39]) using LR recombinase. For pBPGUw-lacZ, the lacZ coding sequence (CDS) was amplified from pCaSpeR-hs-lacZ and subcloned into HindIII-digested pBPGUw. For pBPGUw-R15F01-lacZ, the R15F01 fragment was recombined into pBPGUw-lacZ from pENTR-TOPO-R15F01 using LR recombinase. For pBPGUw-(D1 \~D8 or del1 \~del4)-lacZ, each truncated fragment of R15F01 was amplified from pBPGUw-R15F01 and subcloned into AatII/NaeI-digested pBPGUw-R15F01-lacZ. For pBPGUw-(D1, D7, or del4)-GAL4, each truncated fragment of R15F01 was amplified and subcloned into AatII/NaeI-digested pBPGUw-R15F01. For pBPGUw-trh47 or trh67, each fragment ([@bib46]) was amplified from genomic DNA and subcloned into AatII/NaeI-digested pBPGUw-R14E10. For pBPGUw-svbE6B-(D1-2, D3-6 or D1-6)-lacZ, each chimeric fragment was amplified from genomic DNA and plasmids containing a R15F01 fragment and subcloned into AatII/NaeI-digested pBPGUw-R15F01-lacZ. For pBPGUw-3×UAS-GAP43GFP and pBPGUw-3×UAS-R15F01-GAP43GFP, the GFP CDS with the GAP43 palmitoylation sequence was amplified from pUbi-GAP-CAAX ([@bib25]) by PCR and subcloned into HindIII-digested pBPGUw (pBPGUw-GAP43GFP). A 3×UAS fragment were generated by annealing two oligo DNAs and subcloned into AatII/NeaI-digested pBPGUw-GAP43GFP. A R15F01 fragment fused to 3×UAS was amplified by PCR and subcloned into AatII/NeaI-digested pBPGUw-GAP43GFP. The primer sequences used in this study are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Transgenic strains were generated by φC31-mediated transgene integration into the attP target sites of *attP2*, *attP40*, or *ZH-51C *([@bib2]; [@bib15]) using plasmid DNAs constructed as described above. Plasmid DNA injections were performed in our laboratory or by BestGene. Information about DNA constructs using the *attP* landing site is included in the table of fly strains. Most of the *lacZ* reporters were integrated into the *attP40* site, except for *del1-lacZ*, s*vbE6B-D1-2-lacZ*, and *svbE6B-D1-6-lacZ*. Although one strain of *del1-lacZ* integrated at the *attP40* site was obtained, it had a frame-shift mutation in the *lacZ* CDS. Therefore, we used this *attP40* line with the frameshift to observe the adult body color ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}) and the *ZH-51C* line to analyze the embryonic β-gal expression ([Figure 4---figure supplement 1H](#fig4s1){ref-type="fig"}). *svbE6B-D1-2-lacZ* and *svbE6B-D1-6-lacZ* were also integrated into the *ZH-51C* site because we could not obtain transformants in which these transgenes were integrated into the *attP40* site.

Live imaging {#s4-3}
------------

Embryos were prepared for live imaging as previously reported ([@bib25]). Imaging was performed using an Olympus FV-1000 with a 60x oil immersion objective (PLAPON 60XO, numerical aperture 1.42, Olympus) at 25°C ([Figure 1C](#fig1){ref-type="fig"}) or a Zeiss LSM800 with a 63x oil immersion objective (Objective Plan-Apochromat 63x/1.4 Oil DIC, Zeiss) ([Figure 1B](#fig1){ref-type="fig"}) at 25°C with a setting below saturated signal intensity. Images were processed using FIJI software (<https://fiji.sc/>), and all projection views were generated using the custom FIJI plugin CoordinateShift (written by Housei Wada, <https://signaling.riken.jp/en/en-tools/imagej/>). 'XY' showed the Z-projection view. 'YZ' and 'XZ' showed the X-projection and Y-projection views of a boxed area in the 'XY' panels. The range of intensity was adjusted using FIJI software, avoiding saturation of the signal.

Immunohistochemistry {#s4-4}
--------------------

Embryos were dechorionated in 50% bleach for 2 min and fixed in 1:1 4% PFA containing 1 mM CaCl~2~ and heptane for 20 min at room temperature. The vitelline membrane was removed by shaking in 1:1 methanol and heptane. Embryos were washed in PBSTwx (PBS with 0.2% Tween 20% and 0.2% Triton X-100) 3 times for 15 min each and blocked in PBSTwx with 1% BSA for 60 min at room temperature. Samples were stained with the primary antibody at 4 °C overnight and washed in PBSTwx 3 times for 15 min each. Secondary antibody or phalloidin staining was performed at room temperature for 3 hr. The antibodies used in this study are listed in the Key Resources Table. For dpERK antibody staining, the fluorescent signal was amplified using the Tyramide Signal Amplification system with anti-mouse IgG-biotin, Reagents A and B in the ABC kit, and Cy3 Tyramide. After staining, the embryos were washed in PBSTwx 3 times for 15 min each and mounted in Vectashield Mounting Medium with DAPI (Vector Laboratories) or SlowFade Diamond Antifade Mountant with DAPI (Molecular Probes).

Images of fixed embryos were taken using a Zeiss Apotome.2 equipped with ORCA-Flash V2 (Hamamatsu Photonics) and a 20x dry objective (Objective Plan-Apochromat 20x/0.8, Zeiss) or a 63x water immersion objective (Objective C-Apochromat 63x/1.20 W, Zeiss) with a setting below saturated signal intensity unless otherwise noted. For [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, images of fixed embryos were taken using an Olympus FV-1000 with a 20x objective lens (UPLSAPO 20X numerical aperture 0.75, Olympus). Images were processed using FIJI software, and all projection views were generated using a custom FIJI plugin CoordinateShift (<https://signaling.riken.jp/en/en-tools/imagej/>). The Z-projection, X-projection, and Y-projection regions were manually determined for each image. 'XY(epi)' showed the Z-projection view at the surface-epidermis level, and 'XY(tra)' showed the Z-projection view at the level inside the trachea. 'YZ' and 'XZ' showed the X-projection and Y-projection views of a boxed area in the 'XY' panels. All images were acquired with a 63x water immersion objective (Objective C-Apochromat 63x/1.20 W, Zeiss) were smoothed with a 1-Sigma (radius) Gaussian Blur filter. The dynamic range of intensity was adjusted while avoiding saturation of the signal. For the *D*E-cad signal, the intensity was adjusted to show the epithelial tissue geometry more clearly; therefore, some dense signals were oversaturated. For the *svbE6B* chimeric reporter analyzes in [Figure 5B--F](#fig5){ref-type="fig"}, the β-gal signal was collected and adjusted using the same parameters among strains using the same transgene landing site (*attP40* or *ZH-51c*). For the *3 × UAS* chimeric reporter analyzes in [Figure 5G--I](#fig5){ref-type="fig"}, the GFP signal was collected and adjusted using the same parameters. All images were converted into 8-bit images and assembled using Adobe Illustrator for figures. In all images, the anterior side is to the left, and the dorsal side is up. Since tracheal morphogenesis is left-right symmetric, right-side images were flipped to adjust the directions of the anterior-posterior and dorsal-ventral axes.

Cell counting {#s4-5}
-------------

The numbers of Trh-positive cells and β-gal-positive cells were counted manually using Z-stack images taken by a Zeiss ApoTome.2 and FIJI software with the Cell Counter plug-in. The 4th, 5th, and 6th tracheal metameres of each embryo were used for this quantification. Boxplots and beeswarms were drawn, and statistical analyzes were performed using R software (<https://www.r-project.org/>). Exact Wilcoxon-Mann-Whitney Tests were performed using the Wilcox_test function from the coin package. Steel-Dwass tests were performed using pSDCFlig from the NSM3 package with the Asymptotic method.

Adult fly imaging {#s4-6}
-----------------

Images of 1-day-old adult flies were taken using a Leica S8APO stereomicroscope equipped with an Olympus AIR01 digital camera. Images were adjusted using Adobe Photoshop and assembled using Adobe Illustrator for figures.
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Decision letter

Schejter

Eyal D

Reviewing Editor

Weizmann Institute of Science

Israel

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Two-step regulation of *trachealess* ensures tight coupling of cell fate with tubular architecture in *Drosophila* trachea\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom served as a guest Reviewing Editor, and the evaluation has been overseen Utpal Banerjee as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The study described in the submitted manuscript from Kondo and Hayashi explores the genetic and morphological programs underlying the initial developmental stages of the tracheal system in *Drosophila* embryos. Major findings described include:

• The bHLH-PAS transcription factor Trachealess (Trh), long considered a \"master regulator\" of tracheal system development, is shown to govern tracheal system differentiation only following invagination and segregation of (future) tracheal cells from the surface ectodermal layer, but to be dispensable for the definition of the tracheal domain and the invagination process itself.

• Restriction of Trh activity to differentiating cells is achieved by refining the relatively broad initial expression pattern of *trh*, so that expression is maintained in invaginated cells but extinguished in cells that remain at the surface. The authors identify a 5\' regulatory element, *R15F01*, which appears to harbor the sequences critical both for maintenance and silencing of *trh* expression in relevant cells.

• Data is provided in an attempt to support a scenario where Trh governs tracheal system differentiation via regulation of a RhoGTPase-actomyosin cytoskeletal network.

Essential revisions:

This is a valuable and interesting study whose primary message is the coupling of morphogenesis (in this case- invagination of surface epidermis) with the expression pattern of a key transcription factor that governs further tissue differentiation. All three reviewers viewed both the subject matter and the quality of much of the experimental work with high regard. All three, however, raised a number of non-trivial concerns regarding the significance of different results obtained, as well as aspects of the text, which seemed at times excessive in its interpretation of the data. The major critiques and suggested ways of addressing them include the following:

I\) The reported results can be divided conceptually into three groups-

1\) The role of Trh: the claim that Trh function is required only subsequent to invagination is a key observation at the heart of this study, which also contrasts with current \"dogma\" in the field. It is imperative therefore that a strong case be made.

• Can the authors demonstrate that invagination followed by retraction is a prevalent phenotype in *trh* mutant embryos (i.e.- how often is it observed)?

• Can this be shown for full nulls (rather than/in addition to the hypomorphic *trh^1^* allele)?

• Finally- the authors should explicitly address and discuss the discrepancies between their observations and those of previous studies in the Results or Discussion sections.

2\) Upstream of *trh*: There was general agreement that the strong part of the study was the focus and analysis of how *trh* expression is regulated in invaginated vs. surface cells, and the identification of the *R15F01* regulatory element as the key mediator of this program. Two additional experiments that could support and provide added significance to this notion were requested:

• Assessment of whether driving *trh* expression using *R15F01* alone is sufficient for rescue of the *trh* mutant phenotype.

• Express GFP throughout the embryonic epidermis (e.g. via da-GAL4) via a UAS-based construct which also harbors *R15F01*, and examine whether GFP expression is silenced in the surface epidermal cells and maintained in invaginated cells of nascent salivary glands (an analogous tubular organ system). If this were to be the case, it would considerably strengthen the notion that the enhancing and silencing functions of *R15F01* may indeed be sensitive to \"tissue architecture\", as claimed in the text.

3\) Downstream of *trh*: Two of the reviewers found multiple problems and weaknesses in the sections on downregulation of Rho activity (possibly via Cv-c) and subsequent effects on actomyosin functions as a mechanism via which Trh governs tracheal morphogenesis. These related to the quality and interpretation of the data, and to the lack of coherent cellular and molecular scenarios that could account for formation of a tubular network. Given the extent of these criticisms, it appears premature to include this aspect of the study- certainly in its present state- in the manuscript, and the consensus among the reviewers is to remove it altogether. This would include the second and third sections of the Results. It is recommended, however, that demonstrations showing that invaginated tracheal cells have different expression or activation of markers than the surface epidermis be retained in some fashion, in order to support the notion of distinct fates. The authors could also speculate on possible downstream mechanisms on the basis of the Trh target list they compiled (Figure 3---figure supplement 2).

This shortening of the text should not detract from the significance of the remaining portions of the study. Characterization of the cell biological program governed by *trh* will certainly merit future publication on its own.

II\) The reviewers felt that a \"toning down\" of some of the language used in the text was called for, to better reflect just what the data was able to show. Much of this centered on properly interpreting the role of Trh, where two specific issues were raised:

• The *trh* mutant phenotype implies that Trh function is necessary for maintaining an invaginated structure, but stating that Trh mediates \"tube formation\" and \"tube architecture\" is not warranted. This (excessive) terminology appears throughout the text and in key section headings as well as the title of the paper. Alternative terms such as \"morphogenesis\" (Thus- \"Two-step regulation of *trachealess* ensures tight coupling of cell fate with morphogenesis in *Drosophila* trachea\" for the title) and \"invaginated structure\" rather than \"tube\"-containing terms should be substituted for the ones now used.

• Furthermore, *trh* expression may be turned on/maintained in the invaginated cells not because these cells somehow sense their new morphology, but because they have adopted a non-epidermal fate. This interpretation should be brought up and included when discussing the significance of the results.

10.7554/eLife.45145.022

Author response

> Essential revisions:
>
> This is a valuable and interesting study whose primary message is the coupling of morphogenesis (in this case- invagination of surface epidermis) with the expression pattern of a key transcription factor that governs further tissue differentiation. All three reviewers viewed both the subject matter and the quality of much of the experimental work with high regard. All three, however, raised a number of non-trivial concerns regarding the significance of different results obtained, as well as aspects of the text, which seemed at times excessive in its interpretation of the data. The major critiques and suggested ways of addressing them include the following:
>
> I\) The reported results can be divided conceptually into three groups-
>
> 1\) The role of Trh: the claim that Trh function is required only subsequent to invagination is a key observation at the heart of this study, which also contrasts with current \"dogma\" in the field. It is imperative therefore that a strong case be made.
>
> • Can the authors demonstrate that invagination followed by retraction is a prevalent phenotype in trh mutant embryos (i.e.- how often is it observed)?

We observed eight embryos at stage 12 and ten embryos at stages 15\~16 in the heteroallelic combination of two TALEN alleles and the appearance of invaginated structures at stage 12 and their disappearance at stages 15\~16, as shown in Figure 1F and G, respectively, with 100% penetrance. These TALEN alleles are supposed to be null, as described below. We have added this statement in the Results section (subsection "*trh* is required to maintain invaginated structures", last paragraph).

> • Can this be shown for full nulls (rather than/in addition to the hypomorphic trh^1^ allele)?

As we previously reported (Kondo et al., 2014), each TALEN allele has a frameshift mutation in the most upstream common exon among all isoforms. We predicted the amino acid sequences of the *trh^A14-3^* and *trh^B16-11^* mutants and demonstrated that both frameshift mutations lead to premature translational termination and the loss of the PAS A, PAS B and transcription activation domains in Figure 1---figure supplement 2A. The A14-3 allele also loses the bHLH domain. In addition, we showed that no anti-Trh signal was observed in the *trh^A14-3/B16-11^* mutants in Figure 1---figure supplement 2B. These results indicate that these alleles are null. We have shown that the heteroallelic combination of these two alleles replicated the phenotype observed with *trh^1^* (Figure 1D-G).

> • Finally- the authors should explicitly address and discuss the discrepancies between their observations and those of previous studies in the Results or Discussion sections.

*The trh* mutant phenotype that we observed contradicted previous reports claiming that *trh* is required for invagination(Isaac and Andrew, 1996; Wilk et al., 1996). This conclusion was based mainly on the observation of a complete lack of tracheal structures and late tracheal markers in stage 15 or later. By looking closely into published data in the literature, we noted that signs of tracheal invagination are detectable in the early stage but are lost later in *trh* mutants (see, for example, Chung et al., 2011, Figure 2B, J, M, Figure 4B, E). The live imaging data in our present study provided definitive proof for the role of *trh* in the maintenance of the invaginated structures. We stated this point in the Discussion.

> 2\) Upstream of trh: There was general agreement that the strong part of the study was the focus and analysis of how trh expression is regulated in invaginated vs. surface cells, and the identification of the R15F01 regulatory element as the key mediator of this program. Two additional experiments that could support and provide added significance to this notion were requested:
>
> • Assessment of whether driving trh expression using R15F01 alone is sufficient for rescue of the trh mutant phenotype.

*R15F01* activity is later and/or limited to a smaller number of trachealcells than *R14E10* (Figure 3---figure supplement 2). *trh*-overexpression by *R15F01-GAL4* in the *trh* mutants partially rescued tracheal morphogenesis (Figure 3---figure supplement 3). While the invagination anomaly of the *trh* mutants was not fully rescued at stage 12, *R15F01*-driven *trh* was able to maintain invaginated structures, although they showed an incomplete branching pattern, possibly due to a limited number of *R15F01-*positivecells. These results are consistent with the idea that *R15F01* activity is maintained in invaginated cells.

> • Express GFP throughout the embryonic epidermis (e.g. via da-GAL4) via a UAS-based construct which also harbors R15F01, and examine whether GFP expression is silenced in the surface epidermal cells and maintained in invaginated cells of nascent salivary glands (an analogous tubular organ system). If this were to be the case, it would considerably strengthen the notion that the enhancing and silencing functions of R15F01 may indeed be sensitive to \"tissue architecture\", as claimed in the text.

We agree with the reviewer that this experiment is an important challenge, and we have performed additional experiments following the reviewer's suggestion. We constructed 3xUAS and 3xUAS-*R15F01*-fused GFP reporters and integrated them into the same landing site (attP2). When we crossed them with arm-GAL4, which is an epithelial ubiquitous GAL4 driver, the 3xUAS-GFP reporter activity was detected ubiquitously with intense activity in surface epidermal and tubular hindgut cells. Since the reporter activity in salivary gland cells was relatively weak in our experimental setting, we focused on these two tissues. When we crossed the 3xUAS-*R15F01*-fused GFP reporter with arm-GAL4, epidermal GFP expression was repressed, while hindgut GFP expression was still detectable. Embryos harboring only the 3xUAS-*R15F01*-fused GFP reporter without arm-GAL4 did not show hindgut GFP expression, indicating that the hindgut activity was driven by GAL4. These results are also consistent with the notion that the silencing activity of *R15F01* is prominent in surface epidermal cells but is not functional in the cells of internal tubular organs relocated from the surface epidermis. We have added these results as Figure 5G-I.

> 3\) Downstream of trh: Two of the reviewers found multiple problems and weaknesses in the sections on downregulation of Rho activity (possibly via Cv-c) and subsequent effects on actomyosin functions as a mechanism via which Trh governs tracheal morphogenesis. These related to the quality and interpretation of the data, and to the lack of coherent cellular and molecular scenarios that could account for formation of a tubular network. Given the extent of these criticisms, it appears premature to include this aspect of the study- certainly in its present state- in the manuscript, and the consensus among the reviewers is to remove it altogether. This would include the second and third sections of the Results. It is recommended, however, that demonstrations showing that invaginated tracheal cells have different expression or activation of markers than the surface epidermis be retained in some fashion, in order to support the notion of distinct fates. The authors could also speculate on possible downstream mechanisms on the basis of the Trh target list they compiled (Figure 3---figure supplement 2).
>
> This shortening of the text should not detract from the significance of the remaining portions of the study. Characterization of the cell biological program governed by trh will certainly merit future publication on its own.

We appreciate the constructive advice from the reviewers and agree that removing this part makes the paper simpler and strengthens the message of the paper. According to the reviewer's suggestion, we decided to remove the section related to factors downstream of Trh and describe possible downstream mechanisms from the Discussion section. We will publish these results elsewhere in the future.

> II\) The reviewers felt that a \"toning down\" of some of the language used in the text was called for, to better reflect just what the data was able to show. Much of this centered on properly interpreting the role of Trh, where two specific issues were raised:
>
> • The trh mutant phenotype implies that Trh function is necessary for maintaining an invaginated structure, but stating that Trh mediates \"tube formation\" and \"tube architecture\" is not warranted. This (excessive) terminology appears throughout the text and in key section headings as well as the title of the paper. Alternative terms such as \"morphogenesis\" (Thus- \"Two-step regulation of trachealess ensures tight coupling of cell fate with morphogenesis in Drosophila trachea\" for the title) and \"invaginated structure\" rather than \"tube\"-containing terms should be substituted for the ones now used.

According to the reviewer's suggestion, we have changed terms containing "tube" to "invaginated structures" or "morphogenesis".

> • Furthermore, trh expression may be turned on/maintained in the invaginated cells not because these cells somehow sense their new morphology, but because they have adopted a non-epidermal fate. This interpretation should be brought up and included when discussing the significance of the results.

We agree that escape from surface epidermis to the inside of the embryo could allow cells to acquire a non-epidermal fate instead of the forced induction of tracheal fate only in invaginated cells. Therefore, we further discussed the possible mechanisms to connect *trh* expression and epithelial structures in the Discussion section (subsection "Control mechanisms of *R15F01* CRM activity and Trh maintenance", first paragraph).
